Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2026)

Spyre Therapeutics' Receivables - Accured history runs 8 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• Quarterly Receivables - Accured rose 35.29% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 35.29% YoY) and the FY2025 annual result came in at $4.5 million, up 32.35% from the prior year.
• Receivables - Accured was $4.6 million for Q1 2026 at Spyre Therapeutics, up from $4.5 million in the prior quarter.
• Across five years, Receivables - Accured topped out at $4.6 million in Q1 2026 and bottomed at $100000.0 in Q4 2022.
• A 5-year average of $2.1 million and a median of $1.8 million in 2024 frame the typical range for Receivables - Accured.
• Annual changes were most pronounced in 2022 — Receivables - Accured changed 0.0% — and 2024, when it soared 1700.0%.
• Spyre Therapeutics' Receivables - Accured stood at $100000.0 in 2022, then jumped by 800.0% to $900000.0 in 2023, then surged by 277.78% to $3.4 million in 2024, then jumped by 32.35% to $4.5 million in 2025, then climbed by 2.22% to $4.6 million in 2026.
• Business Quant data shows SYRE's Receivables - Accured at $4.6 million in Q1 2026, $4.5 million in Q4 2025, and $3.6 million in Q3 2025.